Merck & Co. Inc and Astra Zeneca have received FDA approval for Lynparza, a PARP inhibitor meant to treat prostate cancer. The drug was previously approved to treat breast and oral cancers. The approval came much earlier than expected. Prostate cancer is the second-most commonly diagnosed cancer in men in the US. Merck’s results for […]